Related Experiment Videos
Niceritrol prevents the decrease in red blood cell 2,3-diphosphoglycerate and neuropathy in streptozotocin-induced
N Hotta1, J Nakamura, H Kakuta
1Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Journal of Diabetes and Its Complications
|July 1, 1995
Summary
Diabetic neuropathy is linked to low red blood cell 2,3-diphosphoglycerate. Niceritrol improved nerve function and blood flow in diabetic rats by addressing hypoxia, not blood sugar.
Area of Science:
- Biochemistry
- Neuroscience
- Endocrinology
Background:
- Nerve ischemia/hypoxia contributes to diabetic complications.
- Red blood cell 2,3-diphosphoglycerate (2,3-DPG) regulates tissue oxygenation.
- The link between 2,3-DPG and diabetic neuropathy requires further investigation.
Purpose of the Study:
- To investigate the relationship between RBC 2,3-DPG and diabetic neuropathy.
- To assess the impact of the vasodilator niceritrol on 2,3-DPG levels and neuropathy in diabetic rats.
Main Methods:
- Induction of diabetes in rats using streptozotocin.
- Measurement of motor nerve conduction velocity and sciatic nerve blood flow.
- Analysis of red blood cell 2,3-DPG, serum cholesterol, and triglyceride levels.
Main Results:
- Diabetic rats exhibited lower RBC 2,3-DPG, reduced nerve conduction velocity, and impaired sciatic nerve blood flow.
- Niceritrol treatment normalized these parameters in diabetic rats without affecting hyperglycemia.
- Positive correlations were observed between 2,3-DPG and nerve blood flow, and nerve conduction velocity and 2,3-DPG.
Conclusions:
- Ischemia/hypoxia is a key factor in diabetic neuropathy development.
- Niceritrol demonstrates therapeutic potential for diabetic neuropathy by mitigating endoneurial hypoxia.